TRAVERE THERAPEUTICS, INC. Payments to Acquire Available-for-sale Securities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Payments to Acquire Available-for-sale Securities of $29.52 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-08-03
- TRAVERE THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $29.52M.
- TRAVERE THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $31.34M, a 62.47% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $36.21M, a 17.44% decline year-over-year.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 9 month as first filed |
|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $29.52M 10-Q · filed 2018-08-03 | ||
| 2018-03-31 | $29.52M 10-Q · filed 2018-07-06 | |||
| 2017-09-30 | $31.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $67.55M derived: sum of 2 quarters · filed 2018-08-03 | $67.55M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $36.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $36.21M 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-07-06 | |||
| 2016-09-30 | $83.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $127.36M derived: sum of 2 quarters · filed 2017-11-07 | $152.02M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $43.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $68.52M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $24.65M 10-Q · filed 2017-05-05 | |||
| 2015-09-30 | $94.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $94.79M derived: sum of 2 quarters · filed 2016-11-04 | $94.79M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2014-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $7.48M derived: sum of 2 quarters · filed 2015-11-06 | $10.15M 10-Q · filed 2015-11-06 | $10.15M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $4.89M 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $2.67M 10-Q · filed 2015-05-11 | |||
| 2013-09-30 | $3.43M 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |